Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent agents being explored. There are several questions surrounding the sequencing and selection of these agents, and clinical trials exploring their efficacy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.

In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, and Othman-Al Sawaf, MD, University Hospital of Cologne, Cologne, Germany, who discuss the latest updates with the use of BTK inhibitors in CLL. Topics addressed include the management of double-refractory patients, the efficacy and toxicity of covalent and non-covalent BTK inhibitors, the sequencing of these agents, and more.

The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.